RPRX Royalty Pharma plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPRX

Price (delayed)

$56.45

Market cap

$32.51B

P/E Ratio

29.55

Dividend/share

$0.91

EPS

$1.91

Enterprise value

$40.88B

?
Relative Growth: Rel. Growth: 72
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 80

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
The company's quick ratio has surged by 69% YoY and by 10% QoQ
The revenue has increased by 8% YoY and by 2.6% from the previous quarter
The P/E is 43% higher than the last 4 quarters average of 20.6 but 36% lower than the 5-year quarterly average of 46.4
The net income has contracted by 24% YoY but it has grown by 7% from the previous quarter
Royalty Pharma's debt has increased by 18% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.royaltypharma.com
Peers: ANIP ABT LLY

Key stats

What are the main financial stats of RPRX

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
0.04%
1 week
-0.83%
1 month
2.88%
1 year
57.51%
YTD
46.09%
QTD
0.68%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.44B
Gross profit
$2.44B
Operating income
$1.59B
Net income
$827.29M
Gross margin
100%
Net margin
33.9%
Royalty Pharma's net margin has decreased by 30% YoY but it has increased by 4.6% QoQ
The net income has contracted by 24% YoY but it has grown by 7% from the previous quarter
The operating margin has declined by 22% year-on-year
The operating income has contracted by 16% YoY

Price vs fundamentals

How does RPRX's price correlate with its fundamentals

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
RPRX P/E details
P/E
29.55
P/B
3.28
P/S
10.1
EV/EBIT
35.13
EV/EBITDA
35.13
EV/Sales
16.75
The P/E is 43% higher than the last 4 quarters average of 20.6 but 36% lower than the 5-year quarterly average of 46.4
Royalty Pharma's EPS has decreased by 23% YoY but it has increased by 7% QoQ
RPRX's P/B is 56% above its 5-year quarterly average of 2.1 and 43% above its last 4 quarters average of 2.3
RPRX's equity is up by 2.3% since the previous quarter
The P/S is 53% above the 5-year quarterly average of 6.6 and 40% above the last 4 quarters average of 7.2
The revenue has increased by 8% YoY and by 2.6% from the previous quarter

Efficiency

How efficient is Royalty Pharma business performance
The ROA has decreased by 30% YoY but it has increased by 4.9% from the previous quarter
RPRX's ROE is down by 22% YoY but it is up by 6% from the previous quarter
The ROIC is down by 21% YoY but it is up by 2.3% QoQ
Royalty Pharma's return on sales has decreased by 19% YoY but it has increased by 5% QoQ

Dividends

What is RPRX's dividend history
Dividend details
DPS
$0.91
Dividend yield
1.61%
Payout ratio
47.6%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 101% more than its total liabilities
The current ratio has surged by 71% year-on-year and by 11% since the previous quarter
The company's quick ratio has surged by 69% YoY and by 10% QoQ
Royalty Pharma's debt is 10% lower than its equity
Royalty Pharma's debt has increased by 18% YoY
The debt to equity has increased by 15% YoY but it has decreased by 2.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.